Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis
Just a month after the FDA signed off on the first US study for an off-the-shelf CAR-T therapy from Cellectis $CLLS, its partners at Servier and Pfizer $PFE now have a green light to begin treating patients in the US with UCART19, an allogeneic therapy for acute lymphoblastic leukemia.
Servier and Pfizer have a deal to co-develop UCART19, initially launching their Phase I CALM trial in the UK last summer in CD19-positive B-cell ALL. Now they can begin treating patients at a number of US centers, including the MD Anderson Cancer Center in Houston, a hotbed of cancer drug research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.